A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of capsule and tablet formulations of CB7630 (abiraterone acetate) taken with and without food in patients with prostate cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

NCT00474383

Prostate Neoplasms

COMPLETED PHASE2

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

NCT00485303

Prostatic Neoplasms Prostate Cancer

COMPLETED PHASE2

A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy

NCT00473512

Prostatic Neoplasms

COMPLETED PHASE1/PHASE2

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

NCT00638690

Prostatic Neoplasms

COMPLETED PHASE3

Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer

NCT00473746

Prostate Neoplasms

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label study (identity of assigned study drug will be known) to evaluate the pharmacokinetics of abiraterone acetate in patients with prostate cancer. The study will be conducted in 4 stages: Stage 1 will measure blood levels after patients take 1 daily dose of abiraterone tablet or capsule formulations with and without food; Stage 2 will measure blood levels of single daily doses of abiraterone tablet formulation taken with or without food in parallel design until disease progression (up to 12 cycles \[28 days per cycle\]); Stages 3 and 4 will evaluate the safety and antitumor effects of abiraterone tablet formulation administered with a low dose glucocorticoid in a fasted state for up to 12 months for each stage. As of Protocol Amendment 4, all patients who have completed 12 cycles of abiraterone acetate treatment and continue to receive clinical benefit from such a treatment will enter Stage 4 and receive abiraterone acetate in a fasted condition with a low-dose glucocorticoid. Patients will continue in Stage 4 for an additional 24 cycles. After patients complete the last study visit, they will be followed every 3 months for disease progression and survival for up to 3 years. Serial pharmacokinetic samples will be collected during Stages 1 and 2. Efficacy and safety will be monitored throughout the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Abiraterone acetate (non-fasting)

Group Type EXPERIMENTAL

Stage 1 Group 1: abiraterone acetate

Intervention Type DRUG

1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.

Stage 1 Group 2: abiraterone acetate

Intervention Type DRUG

1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.

Stage 2: abiraterone acetate

Intervention Type DRUG

1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.

Abiraterone acetate (fasting)

Group Type EXPERIMENTAL

Stage 1 Group 1: abiraterone acetate

Intervention Type DRUG

1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.

Stage 1 Group 2: abiraterone acetate

Intervention Type DRUG

1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.

Stage 2: abiraterone acetate

Intervention Type DRUG

1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.

Stage 3: abiraterone acetate

Intervention Type DRUG

1000 mg tablets/day orally for 12 cycles (28 days/cycle).

Stage 3: glucocorticoid

Intervention Type DRUG

prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).

Stage 4: abiraterone acetate

Intervention Type DRUG

1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).

Stage 4: glucocorticoid

Intervention Type DRUG

prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Stage 1 Group 1: abiraterone acetate

1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.

Intervention Type DRUG

Stage 1 Group 2: abiraterone acetate

1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.

Intervention Type DRUG

Stage 2: abiraterone acetate

1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.

Intervention Type DRUG

Stage 3: abiraterone acetate

1000 mg tablets/day orally for 12 cycles (28 days/cycle).

Intervention Type DRUG

Stage 3: glucocorticoid

prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).

Intervention Type DRUG

Stage 4: abiraterone acetate

1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).

Intervention Type DRUG

Stage 4: glucocorticoid

prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men with histologically, cytologically, or biochemically confirmed adenocarcinoma of the prostate
* On-going androgen deprivation with serum testosterone \<50 ng/dL (\<2.0nmol/L)
* Serum potassium \>=3.5 mmol/L
* Eastern Cooperative Oncology Group (ECOG) Performance Status score \<2 (Karnofsky Performance Status \>=50%)
* No history of adrenal insufficiency or hyperaldosteronism
* Any acute toxicities of prior chemotherapy, radiotherapy have resolved to a NCI CTCAE (version 3.0) grade of \<=1 (chemotherapy induced alopecia and grade 2 neuropathy are excluded from this consideration)
* No radiotherapy, chemotherapy, or immunotherapy within 30 days of administration of the study drug 1 (SD1) on Day 1
* No surgery or local prostatic intervention within 28 days of the first dose (any clinically relevant sequelae from the surgery must have resolved prior to SD1 on Day 1)
* Agrees to protocol-defined use of effective contraception
* Life expectancy \>12 weeks

Exclusion Criteria

* Active or uncontrolled autoimmune disease that may require corticosteroid therapy
* Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
* Uncontrolled hypertension
* Protocol-defined laboratory values
* Clinically significant heart disease as evidenced by a myocardial infarction in the past 12 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease (patients with a history of atherosclerotic vascular disease requiring coronary or peripheral artery bypass surgery may be enrolled provided the surgery occurred at least 2 years prior to enrollment and after consultation with a cardiologist to insure that the disease is stable)
* Other malignancy within the previous 5-years other than basal cell or squamous cell carcinomas of skin with a \>30% probability of recurrence within 12 months
* History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study medication
* Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No